Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...
The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...
Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more ...
Patients with type 2 diabetes who received intravitreal anti-vascular endothelial growth factor (VEGF) injections for diabetic retinopathy were more likely to develop systemic adverse events (AEs) ...
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...
The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...
Panelists discuss how faricimab and aflibercept 8 mg compare in drying and durability and how clinicians manage IOP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback